Galera Therapeutics, Inc. financial data

Symbol
GRTX on OTC
Location
Malvern, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 792 % +37.5%
Debt-to-equity -103 % +9.05%
Return On Equity 6.07 % -57.7%
Return On Assets -125 % -13%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75.5M shares
Common Stock, Shares, Outstanding 75.5M shares +38.7%
Entity Public Float 4.9M USD -96.2%
Common Stock, Value, Issued 75K USD +38.9%
Weighted Average Number of Shares Outstanding, Basic 98.5M shares +81.1%
Weighted Average Number of Shares Outstanding, Diluted 98.5M shares +81.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 235K USD -96.3%
General and Administrative Expense 5.92M USD -47.6%
Operating Income (Loss) -10M USD +49.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.39M USD +76%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -8.99M USD +54.2%
Earnings Per Share, Basic 0 USD/shares +59.3%
Earnings Per Share, Diluted 0 USD/shares +59.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.47M USD -47.1%
Assets, Current 4.9M USD -44.9%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Goodwill 0 USD -100%
Other Assets, Noncurrent 101K USD +4950%
Assets 5M USD -43.8%
Accounts Payable, Current 434K USD +46.6%
Accrued Liabilities, Current 164K USD -73.5%
Liabilities, Current 598K USD -34.6%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 152M USD -0.21%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -460M USD -1.99%
Stockholders' Equity Attributable to Parent -149M USD -4.31%
Liabilities and Equity 5M USD -43.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.24M USD +53.3%
Net Cash Provided by (Used in) Financing Activities 635K USD
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 75.5M shares +38.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.6M USD +66.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.47M USD -47.1%
Deferred Tax Assets, Valuation Allowance 75.8M USD +3.97%
Deferred Tax Assets, Gross 76M USD +3.11%
Operating Lease, Liability 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19M USD +67.9%
Lessee, Operating Lease, Liability, to be Paid 1.4M USD -12.1%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 220K USD +1.38%
Lessee, Operating Lease, Liability, to be Paid, Year One 217K USD +11.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 207K USD -24.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 224K USD +1.82%
Deferred Tax Assets, Operating Loss Carryforwards 53M USD +8.18%
Preferred Stock, Shares Issued 119K shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 633K USD -26.1%
Operating Lease, Payments 3K USD -94.3%
Preferred Stock, Shares Outstanding 119K shares
Depreciation, Depletion and Amortization 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 198K USD -75.4%
Share-based Payment Arrangement, Expense 714K USD -78.6%
Interest Expense 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%